Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 16;125(16):2497-506.
doi: 10.1182/blood-2014-10-606038. Epub 2015 Feb 19.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C Byrd  1 , Richard R Furman  2 , Steven E Coutre  3 , Jan A Burger  4 , Kristie A Blum  1 , Morton Coleman  2 , William G Wierda  4 , Jeffrey A Jones  1 , Weiqiang Zhao  1 , Nyla A Heerema  1 , Amy J Johnson  1 , Yun Shaw  5 , Elizabeth Bilotti  5 , Cathy Zhou  5 , Danelle F James  5 , Susan O'Brien  4
Affiliations

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C Byrd et al. Blood. .

Abstract

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-naïve and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serial assessment of adverse events over time. (A) Grade ≥3 AEs by time to event onset from first dose date. The dashed line denotes a 5% rate; x-axis maximum is 50%. (B) Frequency of grade ≥3 AEs by TN or R/R status.
Figure 2
Figure 2
Response to ibrutinib over time. (A) Median percent change from baseline in the ALC and the sum of the products of lymph node diameters (SPD) in all patients, showing 95% confidence intervals for all patients. (B) Curves for cumulative best response (CR, PR, and PR-L) for all patients (N = 132). Results for TN patients (n = 31) are shown in C and D. Results for R/R patients (n = 101) are shown in E and F.
Figure 3
Figure 3
Hemoglobin levels and platelet counts in all treated patients with baseline anemias and thrombocytopenias, respectively.
Figure 4
Figure 4
PFS. (A) Kaplan-Meier curves of PFS in TN and R/R patients. (B) Kaplan-Meier curves of PFS in patients with del(17p) or del(11q) or without del(17p) or del(11q). (C) Kaplan-Meier curves of PFS from day 365 in patients who achieved CR and PR or PR-L within the first 364 days on study.
Figure 5
Figure 5
OS. (A) Kaplan-Meier curves of OS in TN and R/R patients. (B) Kaplan-Meier curves of OS in patients with del(17p) or del(11q) or without del(17p) or del(11q).
See this image and copyright information in PMC

Comment in

References

    1. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. - PMC - PubMed
    1. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916. - PubMed
    1. Lozanski G, Ruppert AS, Heerema NA, et al. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012;53(9):1743–1748. - PMC - PubMed
    1. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448–5457. - PubMed
    1. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–2506. - PMC - PubMed

Publication types

MeSH terms